JP7570641B2 - 癌の処置又は予防において使用する為のキノリン誘導体 - Google Patents

癌の処置又は予防において使用する為のキノリン誘導体 Download PDF

Info

Publication number
JP7570641B2
JP7570641B2 JP2021535249A JP2021535249A JP7570641B2 JP 7570641 B2 JP7570641 B2 JP 7570641B2 JP 2021535249 A JP2021535249 A JP 2021535249A JP 2021535249 A JP2021535249 A JP 2021535249A JP 7570641 B2 JP7570641 B2 JP 7570641B2
Authority
JP
Japan
Prior art keywords
cancer
formula
compound
pharma
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513517A (ja
JP2022513517A5 (https=
Inventor
ポレッティ，フィリップ
エールリッヒ，ハルトムート
シェラー，ディディエ
タツィ，ジャマル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2022513517A publication Critical patent/JP2022513517A/ja
Publication of JP2022513517A5 publication Critical patent/JP2022513517A5/ja
Application granted granted Critical
Publication of JP7570641B2 publication Critical patent/JP7570641B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
JP2021535249A 2018-12-20 2019-12-19 癌の処置又は予防において使用する為のキノリン誘導体 Active JP7570641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306783.4A EP3669874A1 (en) 2018-12-20 2018-12-20 Quinoline derivatives for use in the treatment or prevention of cancer
EP18306783.4 2018-12-20
PCT/EP2019/086470 WO2020127839A1 (en) 2018-12-20 2019-12-19 Quinoline derivatives for use in the treatment or prevention of cancer

Publications (3)

Publication Number Publication Date
JP2022513517A JP2022513517A (ja) 2022-02-08
JP2022513517A5 JP2022513517A5 (https=) 2023-01-31
JP7570641B2 true JP7570641B2 (ja) 2024-10-22

Family

ID=65200518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535249A Active JP7570641B2 (ja) 2018-12-20 2019-12-19 癌の処置又は予防において使用する為のキノリン誘導体

Country Status (11)

Country Link
US (1) US20220071985A1 (https=)
EP (2) EP3669874A1 (https=)
JP (1) JP7570641B2 (https=)
KR (2) KR20210136969A (https=)
CN (2) CN113543784A (https=)
AU (1) AU2019408244B2 (https=)
BR (1) BR112021012132A2 (https=)
IL (1) IL284124B2 (https=)
MA (1) MA54512A (https=)
MX (1) MX2021007178A (https=)
WO (1) WO2020127839A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN120152971A (zh) * 2022-11-25 2025-06-13 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545798A (ja) 2010-12-15 2013-12-26 スプリコス Ａｉｄｓを処置する為に有用な化合物
JP2016505268A (ja) 2013-01-17 2016-02-25 アビバックス バイオマーカーとしてのｍｉＲＮＡ−１２４
JP2017032361A (ja) 2015-07-30 2017-02-09 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム
WO2017158201A1 (en) 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
JP2018507215A (ja) 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
CN103787992B (zh) * 2014-01-21 2016-04-20 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545798A (ja) 2010-12-15 2013-12-26 スプリコス Ａｉｄｓを処置する為に有用な化合物
JP2016505268A (ja) 2013-01-17 2016-02-25 アビバックス バイオマーカーとしてのｍｉＲＮＡ−１２４
JP2018507215A (ja) 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体
JP2017032361A (ja) 2015-07-30 2017-02-09 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム
WO2017158201A1 (en) 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2016年，26(14)，pp.3307-3312

Also Published As

Publication number Publication date
US20220071985A1 (en) 2022-03-10
EP3669874A1 (en) 2020-06-24
JP2022513517A (ja) 2022-02-08
IL284124A (en) 2021-08-31
IL284124B1 (en) 2025-03-01
CN118986981A (zh) 2024-11-22
KR20210136969A (ko) 2021-11-17
CN113543784A (zh) 2021-10-22
MA54512A (fr) 2021-10-27
WO2020127839A1 (en) 2020-06-25
AU2019408244A1 (en) 2021-07-08
CA3122912A1 (en) 2020-06-25
KR20250117703A (ko) 2025-08-05
AU2019408244B2 (en) 2025-03-20
IL284124B2 (en) 2025-07-01
BR112021012132A2 (pt) 2021-09-08
MX2021007178A (es) 2021-07-07
EP3897639A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP7570641B2 (ja) 癌の処置又は予防において使用する為のキノリン誘導体
JP7762386B2 (ja) ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの非晶質固体分散物
WO2011011199A1 (en) Combination therapies with ck2 modulators
RU2811417C2 (ru) Производные хинолина для применения в лечении или предупреждении рака
CA3122912C (en) Quinoline derivatives for use in the treatment or prevention of cancer
JP7823833B2 (ja) ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの共結晶及びその塩
BR122024023622A2 (pt) Uso de um composto derivado de quinolina para tratamento ou prevenção de câncer
AU2021212316B2 (en) Co-crystals and salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物
EP3858336A1 (en) Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
WO2024263966A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263804A2 (en) Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263972A2 (en) Compositions comprising antineoplastons and methods of treating uncommon cancers
EP4731792A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241001

R150 Certificate of patent or registration of utility model

Ref document number: 7570641

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150